Repositioning Candidate Details
| Candidate ID: | R1309 |
| Source ID: | DB09422 |
| Source Type: | approved |
| Compound Type: | biotech |
| Compound Name: | Soybean oil |
| Synonyms: | Dolichos soja seed oil; Glycine angustifolia seed oil; Glycine gracilis seed oil; Glycine hispida seed oil; Oils, soybean; Phalseolus max seed oil; Phaseolus max seed oil; Soja angustifolia seed oil; Soja hispida seed oil; Soja japonica seed oil; Soja max seed oil; Soja soja seed oil; Soja viridis seed oil; Soya bean seed oil; Soya oil; Soybean oil; Soybean seed oil |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Derived from soybeans, soybean oil is a common vegetable oil and a source of polyunsaturated and saturated fatty acids. It is a complex mixture of triglycerides where per 100 g, soybean oil has 16 g of saturated fat, 23 g of monounsaturated fat, and 58 g of polyunsaturated fat. The major component fatty acids are linoleic (48% - 58%), oleic (17% - 30%), palmitic (9% -13%), linolenic (4% - 11%), and stearic (2.5% - 5.0%). It is used as a cooking oil and lipid emulsion for parenteral nutrition in clinical settings. Soybean oil-based lipid emulsion is the only FDA-approved lipid formulation for clinical use. |
| CAS Number: | 8001-22-7 |
| Molecular Weight: | |
| DrugBank Indication: | Indicated for parenteral nutrition as a source of calories and essential fatty acids when oral or enteral nutrition is not possible, insufficient, or contraindicated. |
| DrugBank Pharmacology: | Soybean oil is a nutrition source that provides a biologically utilizable source of calories and essential fatty acids. It prevents the biochemical lesions of essential fatty acid deficiency (EFAD), and correct the clinical manifestations of the EFAD syndrome by supplying energy and nutrients. |
| DrugBank MoA: | Fatty acids serve as an important substrate for energy production. The most common mechanism of action for energy production derived from fatty acid metabolism is beta oxidation. Fatty acids are also important for membrane structure and function, precursors for bioactive molecules (such as prostaglandins), and as regulators of gene expression. Soybean oil-based lipid emulsion may also cause an increase in heat production, decrease in respiratory quotient, and increase in oxygen consumption following its administration . Soybean oil contents prevent abnormally high triacylglycerol synthesis and its accumulation as lipid droplets in the liver by regulating hepatic lipogenesis and lipolysis. In vitro, soybean oil is shown to prevent downregulation of CYP2C2, CYP2C11 and CYP3A2 mRNA thus maintaining hepatic drug oxidation capabilities. Soybean oil is broken down into free fatty acids that activate PPAR-alpha, which regulate hepatic CYP4A1 that hydroxylate saturated and unsaturated fatty acids. Soybean oil is also shown to prevent up/downregulation of efflux transporters and maintain mRNA levels of hepatic antioxidant enzymes in vitro rat studies . |
| Targets: | Peroxisome proliferator-activated receptor alpha activator |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|